Category: Prostrate cancer

Home / Prostrate cancer

Categories

Niraparib and abiraterone acetate plus prednisone is approved by FDA for BRCA-mutated metastatic castration-resistant prostate cancer

August 2023: The fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.), along with prednisone, has been approved by the Food and Drug Administration for adult pa...

Focal HIFU therapy in prostate cancer

  What does local prostate cancer mean? In Liv Hospital Urology Clinic, HIFU is applied as the primary treatment approach in localized prostate cancer, that is, at the stage where the entire cancer ...

Darolutamide tablets is approved by FDA for metastatic hormone-sensitive prostate cancer

August 2022: Darolutamide (Nubeqa, Bayer HealthCare Pharmaceuticals Inc.) tablets combined with docetaxel were approved by the Food and Drug Administration for adult patients with metastatic hormone-...

Pluvicto is approved by FDA for metastatic castration-resistant prostate cancer

April 2022: The Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) for the treatment of adult patie...

High Intensity Focused Ultrasound

March 2022: HIFU (High Intensity Focused Ultrasound) is a cutting-edge therapy that uses focused, high-energy ultrasound waves to heat and kill cancerous parts of the prostate gland. The target tissue...

The FDA has approved relugolix for the treatment of advanced prostate cancer

August 2021: The first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix (ORGOVYX, Myovant Sciences, Inc.), was approved by the Food and Drug Administration on December 18, 202...

Scan the code